Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial
Rouchelle Sriranjan, Tian Xiao Zhao, Jason Tarkin, Annette Hubsch, Joanna Helmy, Evangelia Vamvaka, Navazh Jalaludeen, Simon Bond, Stephen P Hoole, Philip Knott, Samantha Buckenham, Victoria Warnes, Nick Bird, Heok Cheow, Heike Templin, Paul Cacciottolo, James H F Rudd, Ziad Mallat, Joseph Cheriyan
BMJ Open Oct 2022, 12 (10) e062602; DOI: 10.1136/bmjopen-2022-062602